TheraRadar
← Back
Data updated: Nov 8, 2026

TELIX

Pharma
OncologyGastroenterology Execution: Needs Improvement

TELIX is a pharmaceutical company focused on Oncology, Gastroenterology. Key products include ILLUCCIX.

2021
Since
2
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
2 Small Molecules

TELIX at a Glance

  • Fast trial execution (20 months median completion)

TELIX's Key Drugs

TELIX's core commercial portfolio centers on ILLUCCIX, PIXCLARA, spanning Oncology and Gastroenterology — its most strategically important drugs approved in the last 15 years.

ILLUCCIX
Oncology

Prostate Cancer

Approved 2021
PIXCLARA
Approved 2026

TELIX's Recent FDA Approvals

TELIX secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

PIXCLARA NDA
2026-09-11
floretyrosine f-18

TELIX's Therapeutic Areas

TELIX's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Gastroenterology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 96%
1 drugs Phase 3: 7 Phase 2: 3 Phase 1: 6
Gastroenterology 4%
0 drugs Phase 2: 1

TELIX's Top Competitors

TELIX's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Oncology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology
Takeda big-pharma
Gastroenterology, Oncology
PF PRISM CV big-pharma
Oncology, Gastroenterology
ASTELLAS specialty
Oncology, Gastroenterology

TELIX Pipeline Snapshot

TELIX has 17 active clinical programs from ClinicalTrials.gov — 7 Phase 3, 4 Phase 2 and 6 Phase 1.

7
Phase 3
4
Phase 2
6
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • ILLUCCIX leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 1/7 completed
  • • Speed: 20 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges